Effects of Low Dose Aminoglutethimide in Breast Cancer
Author Information
Author(s): M. Dowsett, A.L. Harris, R. Stuart-Harris, M. Hill, B.M.J. Cantwell, I.E. Smith, S.L. Jeffcoate
Hypothesis
Does combining low dose aminoglutethimide with hydrocortisone provide greater estrogen suppression than aminoglutethimide alone in postmenopausal breast cancer patients?
Conclusion
Combining low dose aminoglutethimide with hydrocortisone leads to greater suppression of estrogen levels compared to aminoglutethimide alone.
Supporting Evidence
- Both treatments suppressed serum oestrone and oestradiol levels.
- AG + HC showed significantly greater suppression of hormone levels compared to AG alone.
- Patients treated with AG alone had increased androstenedione levels.
- Statistical analysis showed significant differences in hormone suppression between treatment groups.
Takeaway
This study found that giving a low dose of a cancer drug with another medicine helps lower hormone levels better than using the drug alone.
Methodology
The study compared hormone levels in two groups of postmenopausal breast cancer patients treated with either aminoglutethimide alone or with hydrocortisone.
Potential Biases
Potential bias due to non-randomized treatment assignment.
Limitations
The treatment groups were not randomized and were derived from geographically separate populations.
Participant Demographics
Postmenopausal women with advanced breast cancer, mean age 61.2 years for AG group and 63.0 years for AG + HC group.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website